Posted by Michael Wonder on 11 May 2021
International IP protection at risk for COVID-19 vaccines
11 May 2021 - The global biotech industry is united in its drive for equitable access to COVID-19 vaccines, but the proposal to waiver IP protection that is before the World Trade Organisation will not overcome the barriers preventing access.
Vaccine production is complicated and few organisations around the world can do it at scale, at low cost, and in compliance with the strict standards and public expectations of manufacturing safety.
Supply chain and distribution challenges, regrettably, are preventing increased vaccine output and delivery.
